Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma
Autor: | Xiao Qin Chen, Liang Wang, Yue Lv, Jing Zhang, Chengcheng Liu, Wei Da Wang, Qi Rong Geng |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2014 |
Předmět: |
Male
Physiology medicine.medical_treatment Cancer Treatment lcsh:Medicine Gastroenterology Hematologic Cancers and Related Disorders Pathogenesis Immune Physiology Medicine and Health Sciences Medicine T-cell lymphoma lcsh:Science Lymph node Multidisciplinary Cancer Risk Factors Age Factors Hematology Middle Aged Prognosis Lymphoma Extranodal NK-T-Cell Survival Rate medicine.anatomical_structure Oncology B symptoms Cytokines Lymphomas Oncology Agents Female medicine.symptom Cancer Prevention Research Article Adult medicine.medical_specialty Adolescent Immunology Disease-Free Survival Young Adult Internal medicine Cancer Detection and Diagnosis Humans Interleukin 9 Aged Chemotherapy business.industry lcsh:R Interleukin-9 Biology and Life Sciences Cancers and Neoplasms Cancer Molecular Development medicine.disease Lymphoma Immune System lcsh:Q business Developmental Biology |
Zdroj: | PLoS ONE, Vol 9, Iss 4, p e94637 (2014) PLoS ONE |
ISSN: | 1932-6203 |
Popis: | Interleukin-9 (IL-9) is more functionally diverse than previously expected, especially with regards to lymphomagenesis. However, the relationship between IL-9 and the clinicopathological features of extranodal NK/T-cell lymphoma is less well established. Patients with this lymphoma in Sun Yat-Sen University Cancer Center between January 2003 and March 2013 were systematically reviewed in an intention-to-treat analysis. Baseline serum IL-9 levels were determined using sandwich enzyme-linked immunosorbent assays. A total of seventy-four patients were enrolled in this study. The mean concentration of serum IL-9 for all patients was 6.48 pg/mL (range: 1.38–51.87 pg/mL). Age, B symptoms and local lymph node involvement were found to be related to high serum IL-9 levels. Patients with low IL-9 levels tended to have higher rates of complete remission. Notably, the median progression-free survival (PFS) and overall survival (OS) were longer in the low IL-9 level group than in the high IL-9 level group (PFS: 68.7 months vs. 28.3 months, P |
Databáze: | OpenAIRE |
Externí odkaz: |